{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro+Esophageal+Junction+Cancer&page=17",
    "query": {
      "condition": "Gastro Esophageal Junction Cancer",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 406,
    "total_pages": 41,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro+Esophageal+Junction+Cancer&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro+Esophageal+Junction+Cancer&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T14:06:20.479Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04396821",
      "title": "A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Gastric Cancer",
        "Gastroesophageal-junction Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "TST001",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab Injection [Opdivo]",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Albumin-Bound Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Transcenta Therapeutics (Hangzhou) Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2020-05-28",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 18,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04396821"
    },
    {
      "nct_id": "NCT01213004",
      "title": "Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gastric Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "respiration correlated CT scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2010-09",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01213004"
    },
    {
      "nct_id": "NCT01684904",
      "title": "Proton Therapy for Esophageal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Esophagus Cancer"
      ],
      "interventions": [
        {
          "name": "Proton radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2013-02-20",
      "completion_date": "2032-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 1,
      "location_summary": "Loma Linda, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01684904"
    },
    {
      "nct_id": "NCT00711412",
      "title": "Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Induction Therapy - Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Induction Therapy - Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Combination Therapy - Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Combination Therapy - Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Combination Therapy - Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Evaluation for response and surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 44,
      "start_date": "2006-05-31",
      "completion_date": "2013-01-30",
      "has_results": true,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00711412"
    },
    {
      "nct_id": "NCT03861793",
      "title": "A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ALKS 4230",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mural Oncology, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2019-02-26",
      "completion_date": "2023-03-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03861793"
    },
    {
      "nct_id": "NCT00780494",
      "title": "Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stomach Cancer",
        "Gastric (Stomach) Cancer",
        "Neoplasm of Cardioesophageal Junction",
        "Gastrointestinal Stromal Tumor (GIST)"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2009-02",
      "completion_date": "2017-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00780494"
    },
    {
      "nct_id": "NCT07262619",
      "title": "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "MSI-H or dMMR Advanced Solid Tumors",
        "MSI-H/dMMR Gastric Cancer",
        "MSI-H/dMMR Colorectal Cancer",
        "MSI-H/dMMR Gastroesophageal-junction Cancer",
        "Endometrial Cancer",
        "Mismatch Repair Deficient or MSI-High Solid Tumors"
      ],
      "interventions": [
        {
          "name": "EIK1005",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab (KEYTRUDA® )",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eikon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2026-01-20",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07262619"
    },
    {
      "nct_id": "NCT03337087",
      "title": "Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Biliary Tract Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Malignant Digestive System Neoplasm",
        "Metastatic Pancreatic Adenocarcinoma",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Sucrosofate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-11-02",
      "completion_date": "2025-08-09",
      "has_results": true,
      "last_update_posted_date": "2024-05-17",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03337087"
    },
    {
      "nct_id": "NCT03544723",
      "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ad-p53",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MultiVir, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-10-01",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Morristown, New Jersey",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03544723"
    },
    {
      "nct_id": "NCT00084617",
      "title": "Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Diffuse Adenocarcinoma of the Stomach",
        "Intestinal Adenocarcinoma of the Stomach",
        "Mixed Adenocarcinoma of the Stomach",
        "Recurrent Gastric Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IIIC Gastric Cancer",
        "Stage IV Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2004-03",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2015-05-01",
      "last_synced_at": "2026-10-23T14:06:20.479Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084617"
    }
  ]
}